Detection of mutations in key genes recurrently mutated in myeloid malignancies. Genomic DNA is isolated from bone marrow aspirates or peripheral blood and the DNA sequence of targeted regions of the ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A, ETNK1, ETV6, EZH2, GATA2, GNAS, GNB1, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NF1, NPM1, NRAS, PDGFRA, PHF6, PPM1D, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, STAT5B, TET2, TP53, U2AF1, WT1, ZRSR2 genes is determined using next-generation sequencing (NGS) technology.
Detects mutations in key genes recurrently mutated in myeloproliferative neoplasms (MPN). DNA sequence of targeted regions of the CALR, CSF3R, JAK2, MPL and SETBP1 genes is determined using next generation sequencing technology.
Detects the JAK2 V617F mutation, which is commonly found in myeloproliferative neoplasms (MPN). DNA is isolated and subjected to allele-specific polymerase chain reaction (PCR) amplification.
Detects JAK2 exons 12 and 13 mutations, which are found a subset of myeloproliferative neoplasms (MPN). DNA sequences of JAK2 exons 12 and 13 are determined using next-generation sequencing technology.
Detects CALR mutations, which are found in a subset of myeloproliferative neoplasms (MPN). DNA sequence of exon 9 of the CALR gene is determined using amplicon-based, next-generation sequencing (NGS) technology.
Cytogenetic abnormalities commonly associated with myeloproliferative neoplasms (MPN) are detected by fluorescence in situ hybridization (FISH). Probes for CKS1B-CDKN2C (1p32.3/1q21.3), 5q (5q-/-5/+5), 7q (7q-/-7), Cen 8 (+8), BCR/ABL1-ASS1 t(9:22), 13q (13q-/-13), 20q (20q-) are included in the MPN FISH Profile
CONTACT US
Genoptix, a NeoGenomics Company
2131 Faraday Ave
Carlsbad, CA 92008
Phone: +1.760.268.6200
Fax: +1.760.268.6201
Client Services
Phone: +1.800.755.1605
Fax: +1.888.755.1604
Email: clientservices@genoptix.com
Medical Director: Derek Lyle, MD
Recent News
NeoGenomics Completes Acquisition of Genoptix, Inc.December 10, 2018 - 9:00 am- NeoGenomics Signs Definitive Agreement to Acquire GenoptixOctober 23, 2018 - 9:00 am
- Genoptix Launches FDA-Authorized BCR-ABL MRDx® TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna® (nilotinib)September 4, 2018 - 8:30 am
HOURS OF OPERATION
Our lab is open six days a week:
5:00am to 6:00pm PT Mon-Fri
7:00am to 3:30pm PT Saturday
For after-hours assistance, your call
will be connected with an on-duty
Client Services Representative.
